Feinberg school of medicine, Medical school in Chicago, Illinois

According to a new study by Northwestern University, Ketamine acts as a speedster of antidepressants, working within hours compared to common antidepressants that can take several weeks.The Northwestern Medicine study has identified for the first time exactly how ketamine works so quickly, and how it might be adapted for use as a drug without the side effects.The study in mice shows ketamine works as a rapid antidepressant by increasing the activity of the very small number of newborn neurons, which are part of an ongoing neurogenesis in the brain.New neurons are always being made at a slow rate. It's been known that increasing the number of neurons leads to behavioral changes. Other antidepressants work by increasing the rate of neurogenesis, in other words, increasing the number of neurons. But this takes weeks to happen.By contrast, ketamine produces behavioral changes simply by increasing the activity of the existing new neurons. This can happen immediately when the cells are activated by ketamine."We narrowed down the population of cells to a small window that is involved," said lead study author Dr. John Kessler, a professor of neurology at Northwestern University Feinberg School of Medicine and the Ken and Ruth Davee Professor of Stem Cell Biology. "That's important because when you give ketamine to patients now, it affects multiple regions of the brain and causes a lot of adverse side effects. But since we now know exactly which cells we want to target, we can design drugs to focus only on those cells."The side effects of ketamine include blurred or double vision, nausea, vomiting, insomnia, drowsiness and addiction. The study was published recently in Nature Communications."The goal is to develop an antidepressant that doesn't take three to four weeks to work because people don't do well during that period of time," Kessler said. "If you are badly depressed and start taking your drug and nothing is happening, that is depressing in itself. To have something that works right away would make a huge difference.""We prove neurogenesis is responsible for the behavioral effects of ketamine," Kessler said. "The reason is these newborn neurons form synapses (connections) that activate the other cells in the hippocampus. This small population of cells acts like a match, starting a fire that ignites a bunch of activity in a lot of other cells that produce the behavioral effects.""However, it has not been understood that the same behavioral changes can be accomplished by increasing the activity of the new neurons without increasing the rate at which they are born," Kessler said. "This obviously is a much more rapid effect."For the study, Northwestern scientists created a mouse in which only the very small population of newborn neurons had a receptor that allowed these cells to be silenced or activated by a drug that did not affect any other cells in the brain.Scientists showed if they silenced the activity of these cells, ketamine didn't work anymore. But if they used the drug to activate this population of cells, the results mirrored those of ketamine. This showed conclusively that it is the activity of these cells that is responsible for the effects of ketamine, Kessler said.( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Feinberg School Of MedicineFOLLOW

Feinberg school of medicine, Latest News

The first study to demonstrate long-term alcohol consumption and associated problems in this cohort found that youth who underwent ... ...

According to a study, a group of researchers discovered that common and rare gene defects influence radiation resistance and sensitivity, paving the possibility for more personalised and effective cancer treatment. ...

An epigenetics drug currently being used for the treatment of blood cancers and rare sarcomas can stop the growth of bladder cancer by activating the immune system, reports a new study in mice. The drug is now being tested in a national clinical tria ...

New York, Oct 5 A study led by Indian-origin doctor Nilay Shah says that the standard approach and ... ...

Researchers involved in a new multi-site international phase III study led by Northwestern Medicine found that a new drug was highly effective in reducing the signs and symptoms of moderate-to-severe eczema. This is the first study to treat moderate- ...

Even low light can disturb sleep, increasing the risk of serious health problems such as blood pressure, diabetes, and obesity in older adults, according to the findings of a study. ...

According to a study, even low light can disturb sleep, increasing the risk of serious health problems such as blood pressure, diabetes, and obesity in older adults. ...

According to a new study by Northwestern University, Ketamine acts as a speedster of antidepressants, working within hours compared to common antidepressants that can take several weeks. ...